What is BeyondSpring Inc?
BeyondSpring Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative cancer therapies. Its primary asset, Plinabulin, a selective immunomodulating microtubule-binding agent, has successfully completed Phase III clinical trials for non-small cell lung cancer (NSCLC) and is being explored for various combination therapies. The company also has a pipeline of three small molecule immune agents in preclinical development, supported by a robust drug discovery platform. Founded in 2010 and headquartered in Florham Park, New Jersey, BeyondSpring Inc. is focused on addressing unmet needs in oncology.
How much funding has BeyondSpring Inc raised?
BeyondSpring Inc has raised a total of $3.8M across 2 funding rounds:
Stock Offering
$3.5M
Debt
$350K
Stock Issuance/Offering (2017): $3.5M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in BeyondSpring Inc
PPP
Public-Private Partnership
What's next for BeyondSpring Inc?
The substantial enterprise-level funding indicates BeyondSpring Inc. is poised for a critical phase of scaling and potential commercialization. Strategic investments suggest a focus on advancing Plinabulin through regulatory pathways and expanding its therapeutic applications. Future endeavors will likely involve further clinical development, strategic partnerships, and market entry preparations, leveraging its robust pipeline and established clinical trial data to solidify its market position in cancer therapy.
See full BeyondSpring Inc company page
